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INTRODUCTION
The survival of children with osteosarcoma has improved
substantially over the last 30 yr. However, as the number of
long-term survivors has increased, there have been increasing
concerns about the potential of late sequelae, especially in the
development of second malignant neoplasms (SMN’s). In pre-
vious reports with long follow-up durations, 2-5% of osteosar-
coma patients developed an SMN at a median interval of 5-
8 yr after osteosarcoma treatment (1-4). The pathogenic mech-
anisms for SMN’s mainly consist of genetic predisposition
and therapy-related factors including chemotherapy and espe-
cially radiation therapy. The most commonly encountered
SMN in osteosarcoma are hematologic malignancy and breast
cancer. Thyroid carcinomas have been described as an SMN
in survivors of leukemia and Hodgkin lymphoma, occurring
after craniospinal irradiation that includes the thyroid gland
(5, 6). However, few studies have reported thyroid carcino-
ma as an SMN in osteosarcoma. Here, we report the occur-
rence of thyroid papillary carcinoma after the treatment of
osteosarcoma in two patients who had neither a family his-
tory of cancer nor history of radiation therapy.
CASE REPORT
Case 1
A 13-yr-old girl visited a local clinic for painful swelling of
right arm after a minor trauma in 1988 (Fig. 1A). A patholog-
ic fracture was suspected upon initial radiographs, and as a
result, an incisional biopsy was performed, which revealed a
fibroblastic osteosarcoma. She was transferred to our institu-
tion after the biopsy and was diagnosed as having in clinical
stage IIB according to the Enneking’s classification. She had
received preoperative chemotherapy consisting of cisplatin
(100 mg/m2, every 3-4 weeks, total 780 mg/m2) and dox-
orubicin (60 mg/m2, every 4 weeks for a total of 293 mg/m2).
Despite the treatment, the patient’s poor clinical response
and her parents’ refusal to definite surgery led us to change
the chemotherapy regimen. After seven courses of bleomycin,
cyclophosphosphamide and actinomycin D, the tumor was
resected with a wide margin, and reconstructed with a tumor
prosthesis-bone cement composite. The changed chemother-
apy regimen was considered to be effective based on the clin-
ical and histologic response, and the patient had received 4
more courses of chemotherapy with the same agents. The
patient complained of dyspnea during the last course of post-
operative chemotherapy and was brought in for a cardiac con-
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Secondary Thyroid Papillary Carcinoma in Osteosarcoma Patients:
Report of Two Cases
We report two cases of papillary thyroid carcinoma occurring after the successful
treatment of osteosarcoma. One of the patients was administered with several alky-
lating agents and topoisomerase II inhibitor as part of the primary treatment of osteo-
sarcoma. The onset of thyroid carcinoma occurred after 5 and 12 yr after cessation
of the osteosarcoma therapy. All the patients involved in this study are alive and
free of their malignancies. There have been eight case reports of these two malig-
nancies occurring in the same patient. Thyroid carcinoma rarely occurs in patients
with osteosarcoma; however, vigilant surveillance and long-term follow-up should
be emphasized for all survivors.
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Accepted : 25 June 2007sultation. The echocardiogram and endomyocardial biopsy
revealed the patient to be afflicted with dilated cardiomy-
opathy, which was consideraed to have been caused by dox-
orubicin. Her cardiac symptoms were mild and well-con-
trolled with diuretics, and she had been doing well for 12
yr until a mass in her neck was discovered.
Fine-needle aspiration cytology revealed papillary carcino-
ma in the right lobe of thyroid. She underwent total thyroidec-
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Fig. 1. (A) A plain radiograph showed pathologic fracture around the surgical neck of the right humerus. The incisional biopsy confirmed
the diagnosis of osteosarcoma. (B) Pathologic examination revealed a papillary carcinoma in the right lobe of thyroid. The tumor cells were
tall and their cytoplasm contained eosinophilic granules and pseudostratified nuclei in several areas (stain, H&E; original magnification,×100).
A B
Fig. 2. (A) An anteroposterior radiograph showed pasteurized autograft-prosthesis composite reconstruction of the proximal tibial osteosar-
coma. (B) Five years after the index operation, a follow-up CT scan shows a calified nodule in the left lobe of the thyroid. (C) The tumor
cells showed typical overlapping, grooved, and ground glass nuclei (stain, H&E; original magnification, ×200).
A
B
Ctomy without neck dissection and a pathologic evaluation of
the tissue revealed the papillary carcinoma of conventional
type (Fig. 1B). The mass had a 1.2 cm diameter, and the tumor
did not invade the thyroid capsule. She has not undergone
radioactive iodine therapy and has been treated on thyroid
replacement therapy. She showed no evidence of either malig-
nancy at 18 yr after the diagnosis of her osteosarcoma and at
4 yr after the diagnosis of her thyroid carcinoma.
Case 2
An 18-yr-old boy was diagnosed with a chondroblastic
type osteosarcoma of the right proximal tibia in 2001. Accord-
ing to the Enneking’s criteria, the osteosarcoma was in clin-
ical stage IIB. After completing two cycles of chemotherapy
that included a high-dose methotrexate, adriamycin, and
cisplatin, he was treated with a limb salvage operation (Fig.
2A). Postoperative chemotherapy was performed with the
same agents used in preoperative chemotherapy. In 2006 (5
yr after the diagnosis of osteosarcoma), a thyroid nodule was
incidentally found on a follow-up chest CT image (Fig. 2B).
The cytologic findings of a fine-needle aspiration were con-
sistent with papillary thyroid carcinoma, and he underwent
a total thyroidectomy with modified radical neck dissection
shortly thereafter. The pathologic evaluation revealed a con-
ventional type papillary carcinoma in the left thyroid lobe
(Fig. 2C). The tumor showed some infiltration into perithy-
roidal soft tissue. A total of 15 lymph nodes were dissected,
10 of which were found to be positive for tumor cells. After
the surgery, he was treated with radioactive 131I and main-
tained on thyroid hormone replacement therapy. Six years
after the diagnosis of osteosarcoma and 1 yr after the diag-
nosis of thyroid carcinoma, he has been and remains free of
malignancies.
DISCUSSION
Thyroid cancer accounted for 7.5% of the SMN’s reported
in a series of childhood survivors of malignancy (7). Most sec-
ond thyroid cancers have been reported to develop after radi-
ation therapy in survivors of leukemia and Hodgkin lym-
phoma. A genetic predisposition to thyroid malignancy has
been observed in familial syndromes such as Pendred, hamar-
toma, and Gardner’s syndromes (8), while familial retinoblas-
toma, Li-Fraumeni, Rothmund-Thomson, and Bloom syn-
dromes were associated with osteosarcoma. In our series, none
of the patients exhibited clinical features consistent with the
aforementioned genetic disease. Moreover, there was no fam-
ily history of genetic disease or malignancy on either of the
maternal and paternal sides. However, there still remains a
possibility that our patients may have a genetic syndrome
such as Rothmund-Thomson syndrome, especially since the
clinical features of this syndrome could be subtle. Genotype
analysis of the RECQL genes including RECQL4 (for Roth-
mund-Thomson syndrome), RECQL2 (for Bloom syndrome),
and RECQL3 (for Werner syndrome) are mandatory to rule
out these syndromes.
Although most second thyroid malignancies develop after
exposure to radiotherapy, none of our patients underwent radi-
ation therapy. Some of the thyroid malignancies may have been
unrelated to the primary tumors, and ocurred as it would in
the general population rather than being related to either the
primary cancer or the therapy. Several etiologic factors for the
second thyroid cancer aside for radiation therapy have been
proposed, such as the sequelae of immune suppression, the
oncogenic potential of systemic chemotherapy, or some com-
binations of these factors. 
Chemotherapy can have numerous long-term effects includ-
ing, most importantly, the leukemogenic effect. There are
several reports on secondary leukemias and myelodysplastic
syndromes in patients treated with multi-agent chemother-
apies for osteosarcoma. Recent reports have emphasized the
concern of treatment-related myelodysplasia/myeloid leukemia
for regimens that use high cumulative doses of alkylating
agents in addition to combination therapy with topoisomerase
II inhibitors. Smith et al. reported 3 cases of thyroid cancer
arising in patients treated with alkylating agents without
radiation (9). They proposed that alkylating agents affected
DNA synthesis by binding directly to DNA. This binding
resulted in damage to the normal and neoplastic cells. In the
current series, the first case was administered with several
alkylating agents and topoisomerase II inhibitor (including
cisplatin, cyclophosphamide, ifosfamide, and adriamycin),
which might have heralded the development of thyroid can-
cer (10).
Eight cases of thyroid carcinoma occurring in association
with osteosarcoma have been reported to date (11-15). Of
the eight, four patients had genetic abnormalities (most com-
monly the Werner syndrome). The Werner syndrome is a he-
reditary systemic disease characterized by premature senility.
The clinical characteristics of the syndrome include small
stature, scleroderma-like skin alterations, juvenile cataracts,
premature facial aging, ectopic calcification, refractory ulcers,
and joint contracture. The most problematic complication
of Werner’s syndrome is malignant tumors. Thyroid cancer,
osteosarcoma, and malignant melanoma are frequently asso-
ciated with this syndrome (16). In our series, no patients show-
ed the clinical features of Werner’s syndrome.
Among the remaining four patients, two underwent radi-
ation therapy, which might have exerted deleterious effects
of radiation scatter on the thyroid area, and the other two
patients did not have genetic abnormalities or risk factors
for SMN’s. The two patients documented in previous reports
and the second patient of the present report would be good
candidates for the screening of unknown genetic predisposi-
tion, including single nucleotide pleomorphism. In conclu-
sion, vigilant surveillance and long-term follow-up should
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